The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma

BackgroundTumor-infiltrating immune cells are important components of tumor microenvironment (TME), and their composition reflects the confrontation between host immune system and tumor cells. However, the relationship between the composition of infiltrating immune cells, prognosis, and the applicab...

Full description

Bibliographic Details
Main Authors: Jiacheng Huang, Lele Zhang, Jianxiang Chen, Dalong Wan, Lin Zhou, Shusen Zheng, Yiting Qiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
HCC
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.744951/full
id doaj-d302ec90e6af4b8cacc15a99c6eeee3c
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Jianxiang Chen
Jianxiang Chen
Jianxiang Chen
Jianxiang Chen
Dalong Wan
Lin Zhou
Lin Zhou
Lin Zhou
Lin Zhou
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Yiting Qiao
Yiting Qiao
Yiting Qiao
Yiting Qiao
spellingShingle Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Jianxiang Chen
Jianxiang Chen
Jianxiang Chen
Jianxiang Chen
Dalong Wan
Lin Zhou
Lin Zhou
Lin Zhou
Lin Zhou
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Yiting Qiao
Yiting Qiao
Yiting Qiao
Yiting Qiao
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
Frontiers in Oncology
HCC
CIBERSORT
PD-L1
immune subtype
prognosis
author_facet Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Jianxiang Chen
Jianxiang Chen
Jianxiang Chen
Jianxiang Chen
Dalong Wan
Lin Zhou
Lin Zhou
Lin Zhou
Lin Zhou
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Yiting Qiao
Yiting Qiao
Yiting Qiao
Yiting Qiao
author_sort Jiacheng Huang
title The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
title_short The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
title_full The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
title_fullStr The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
title_full_unstemmed The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
title_sort landscape of immune cells indicates prognosis and applicability of checkpoint therapy in hepatocellular carcinoma
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-09-01
description BackgroundTumor-infiltrating immune cells are important components of tumor microenvironment (TME), and their composition reflects the confrontation between host immune system and tumor cells. However, the relationship between the composition of infiltrating immune cells, prognosis, and the applicability of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma (HCC) needs systematic examination.MethodsCell-Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) was applied to evaluate the infiltration of immune cells based on The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) cohort. Diagnostic and prognostic models were constructed based on immune cells, and the models were validated by two external cohorts. The relationship between immune cells and PD-L1 was evaluated by Spearman correlation, and the finding was validated in our in-house HCC sample.ResultPatients in TCGA LIHC cohort were classified into six subtypes with different prognosis based on the proportion of tumor-infiltrating immune cells simulated via CIBERSORT. Among 22 types of immune cells, intratumoral PD-L1 mRNA level exhibited linear relationship with the fraction of five types of immune cells (M1 macrophages, plasma cells, CD8+ T cells, resting mast cells, and regulatory T cells), and M1 macrophages showed the strongest relevance (R = 0.26, p < 0.001). Immunohistochemistry of our in-house HCC specimens verified this conclusion. Moreover, intratumoral mRNA levels of M1 macrophage-associated cytokines were positively correlated with PD-L1 level.ConclusionsOur study demonstrated that the prognosis of HCC patients was associated with the pattern of infiltrating immune cells in TME, and macrophage-associated cytokines might be a potential non-invasive marker for predicting the PD-L1 level for HCC patients.
topic HCC
CIBERSORT
PD-L1
immune subtype
prognosis
url https://www.frontiersin.org/articles/10.3389/fonc.2021.744951/full
work_keys_str_mv AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jianxiangchen thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jianxiangchen thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jianxiangchen thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jianxiangchen thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT dalongwan thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT linzhou thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT linzhou thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT linzhou thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT linzhou thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT yitingqiao thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT yitingqiao thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT yitingqiao thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT yitingqiao thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jianxiangchen landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jianxiangchen landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jianxiangchen landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT jianxiangchen landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT dalongwan landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT linzhou landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT linzhou landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT linzhou landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT linzhou landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT yitingqiao landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT yitingqiao landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT yitingqiao landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
AT yitingqiao landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma
_version_ 1716866361664208896
spelling doaj-d302ec90e6af4b8cacc15a99c6eeee3c2021-09-28T06:48:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.744951744951The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular CarcinomaJiacheng Huang0Jiacheng Huang1Jiacheng Huang2Jiacheng Huang3Jiacheng Huang4Jiacheng Huang5Lele Zhang6Lele Zhang7Lele Zhang8Lele Zhang9Lele Zhang10Lele Zhang11Jianxiang Chen12Jianxiang Chen13Jianxiang Chen14Jianxiang Chen15Dalong Wan16Lin Zhou17Lin Zhou18Lin Zhou19Lin Zhou20Shusen Zheng21Shusen Zheng22Shusen Zheng23Shusen Zheng24Shusen Zheng25Yiting Qiao26Yiting Qiao27Yiting Qiao28Yiting Qiao29Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSchool of Medicine, Zhejiang University, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaShulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSchool of Medicine, Zhejiang University, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaShulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, ChinaPharmacy Institute and Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, ChinaKey Laboratory of Elemene Class Anti-Cancer Medicine of Zhejiang Province, Hangzhou, ChinaEngineering Laboratory of Development and Application of Chinese Medicine from Zhejiang Province, Hangzhou, China0Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, School of Medicine, Hangzhou Normal University, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaShulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaBackgroundTumor-infiltrating immune cells are important components of tumor microenvironment (TME), and their composition reflects the confrontation between host immune system and tumor cells. However, the relationship between the composition of infiltrating immune cells, prognosis, and the applicability of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma (HCC) needs systematic examination.MethodsCell-Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) was applied to evaluate the infiltration of immune cells based on The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) cohort. Diagnostic and prognostic models were constructed based on immune cells, and the models were validated by two external cohorts. The relationship between immune cells and PD-L1 was evaluated by Spearman correlation, and the finding was validated in our in-house HCC sample.ResultPatients in TCGA LIHC cohort were classified into six subtypes with different prognosis based on the proportion of tumor-infiltrating immune cells simulated via CIBERSORT. Among 22 types of immune cells, intratumoral PD-L1 mRNA level exhibited linear relationship with the fraction of five types of immune cells (M1 macrophages, plasma cells, CD8+ T cells, resting mast cells, and regulatory T cells), and M1 macrophages showed the strongest relevance (R = 0.26, p < 0.001). Immunohistochemistry of our in-house HCC specimens verified this conclusion. Moreover, intratumoral mRNA levels of M1 macrophage-associated cytokines were positively correlated with PD-L1 level.ConclusionsOur study demonstrated that the prognosis of HCC patients was associated with the pattern of infiltrating immune cells in TME, and macrophage-associated cytokines might be a potential non-invasive marker for predicting the PD-L1 level for HCC patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.744951/fullHCCCIBERSORTPD-L1immune subtypeprognosis